Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

PURPOSE: Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. PATIENTS AND METHODS: We eval...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Bardia, Aditya, Mayer, Ingrid A., Diamond, Jennifer R., Moroose, Rebecca L., Isakoff, Steven J., Starodub, Alexander N., Shah, Nikita C., O’Shaughnessy, Joyce, Kalinsky, Kevin, Guarino, Michael, Abramson, Vandana, Juric, Dejan, Tolaney, Sara M., Berlin, Jordan, Messersmith, Wells A., Ocean, Allyson J., Wegener, William A., Maliakal, Pius, Sharkey, Robert M., Govindan, Serengulam V., Goldenberg, David M., Vahdat, Linda T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2017
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559902/
https://ncbi.nlm.nih.gov/pubmed/28291390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.8297
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi